Tuesday, March 14, 2023
8:00 am – 9:30 am ET

On February 24, 2022, at 5.00 a.m., Russia started its large-scale military offensive on the territory of Ukraine. The shortest month of a year turned out to be the longest bloodshed of a year for Ukrainians and the entire civilized world.

The National Institutes of Health (NIH) has awarded a five-year, $5 million grant to Vanderbilt University Medical Center for continued support of the Brazil Regional Prospective Observational Research in Tuberculosis network, or RePORT-Brazil.

A set of 10 signaling proteins found in the microbe that causes tuberculosis [TB], play a far larger role in regulating the bacterium’s growth, development and behavior than previously thought, according to recent research. The study was led by University of Washington School of Medicine and Seattle Children's researchers..

People have inhabited the Andes mountains of South America for more than 9,000 years, adapting to the scarce oxygen available at high altitudes, along with cold temperatures and intense ultraviolet radiation. A new genomic study suggests that Indigenous populations in present-day Ecuador also adapted to the tuberculosis bacterium, thousands of years before the arrival of Europeans. 

The Stop TB Partnership releases the toolkit for the World TB Day campaign Yes! We Can End TB.

SEATTLE, February 22, 2023 -- Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II study.

SEATTLE, February 22, 2023 -- An 8-week tuberculosis (TB) treatment strategy where additional therapy is reserved only for persistent disease or at relapse led to less overall treatment and similar clinical outcomes compared with the standard 6-month approach, an open-label randomized study showed.

SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference. SimpliciTB was conducted to evaluate the BPaMZ regimen, consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). This combination previously showed high efficacy and treatment shortening potential in both preclinical evaluations and an early-stage clinical study in drug-resistant patients.

The International Union Against Tuberculosis and Lung Disease (The Union) released its first quarterly training and education newsletter for 2023, sharing the latest news and updates from The Union courses.